Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

After adverse event reports in patients with underlying advanced liver damage, FDA requires AbbVie to add risk language to Viekira Pak and Technivie labels. AbbVie may not see much long-term damage, but Merck likely will gain more traction when it enters the hepatitis C market.

You may also be interested in...



Direct-Acting Antivirals Slapped With Black Box On Hepatitis B Risk

FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.

Health And Wellness Weekly Trademark Review 20 July, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel